Laurence Buisseret

13PUBLICATIONS
42CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersTumour immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.

|Nov 26, 2025
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.

Andreas Papagiannis, Samira Majjaj, Francois P Duhoux

|Dec 12, 2023
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Laurence Buisseret, Delphine Loirat, Philippe Aftimos

|Dec 06, 2023
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.

Alex De Caluwe, Emanuela Romano, Philip Poortmans

|Nov 03, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Laurence Buisseret, Delphine Loirat, Philippe Aftimos

|Sep 21, 2023
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00.

Andrea Joaquin Garcia, Mattia Rediti, David Venet

Pageof 3

Frequent Collaborators

6 joint publications

Christos Sotiriou

4 joint publications

Elisa Agostinetto

4 joint publications

Michail Ignatiadis

4 joint publications

Emanuela Romano